C

CRL

CRL

UnknownUnknown

Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.

Insider Sentiment
Based on recent trading activity
10%Bearish
Buy/Sell Ratio2% buys
BearishBullish
CRL Live QuoteReal-time
$327.93
$16.94(-4.91%)1M
Day Range$326.53 – $343.57
Open$337.20
Previous Close$333.25
Volume493.6K
Key Financials & Valuation
Fundamental balance sheet & market metrics
HEALTHCARE
Market Cap$15.97B
P/E Ratio (TTM)362.2
Forward P/E26.2
EPS (TTM)$0.92
Price to Book4.9
Dividend Yield0.65%
Beta (Volatility)1.34
IndustryDIAGNOSTICS & RESEARCH
52-Week RangeCurrent: $327.93 (78%)
Low: $146.20High: $379.63
Wall Street Consensus
Strong Buy
Analyst Rating
4.8/ 5.0
Target Price
$350.57+133.7% upside

Insider Buys

4

$1.26M

Insider Sales

21

$54.79M

Total Volume

$56.05M

25 transactions

Net Activity

$53.53M

Net selling

Proprietary Ratings
Calculated from Form 4 transactions
80CONFIDENCE

Sentiment Rating

Strong Accumulation

CEO Conviction Index

High Conviction Accumulation

Key Drivers

  • •Heavy distribution: sales represent 98% of total transaction value.
  • •Cluster buying: 4 unique insiders purchased shares, showing strong alignment.
  • •CEO buying activity detected. When chief executives put their own money at risk, it is historically a strong bullish signal.
  • •CFO buying activity detected. Statistical studies show CFO purchases have high predictive power due to their direct visibility into balance sheet details.
  • •High accumulation: total purchase value exceeds $1M.
  • •Significant liquidation: total sale value exceeds $10M.
Score Methodology

The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:

  • +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
  • +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
  • +15CEO Buying: CEO committing own capital shows high conviction.
  • +10CFO Buying: CFO purchasing shares shows financial alignment.
Top Insiders
Most active traders
F
1

Foster James C

Dir

1 buys4 sells

$44.26M total

P
2

Parisotto Shannon M

CEVP, Disc, Safety Assessment

0 buys5 sells

$4.01M total

G
3

Girshick Birgit

CEO

1 buys1 sells

$2.07M total

K
4

Knell Michael Gunnar

SVP, Finance, CAO

0 buys1 sells

$1.73M total

W
5

Wallman Richard F

Dir

0 buys1 sells

$1.65M total

Trading History
CRL insider transactions from SEC Form 4 filings
DateInsiderTypeSharesPriceValueFiling

Oct 22, 2026

4 weeks ago

Foster James C

Dir

Director
Sell24.0K$350.00$8.41M

Oct 21, 2026

1 months ago

Parisotto Shannon M

CEVP, Disc, Safety Assessment

EVP
Sell2.2K$344.41$743K

Oct 5, 2026

1 months ago

Parisotto Shannon M

CEVP, Disc, Safety Assessment

EVP
Sell981$308.44$303K

Sep 30, 2026

1 months ago

Coleman Glenn

EVP, CFO

CFO
Buy10$297.43$3K

Aug 25, 2026

2 months ago

Foster James C

Dir

Director
Sell33.6K$300.00$10.07M

Aug 18, 2026

3 months ago

Andrews Nancy C

Dir

Director
Sell573$285.24$163K

Aug 19, 2026

3 months ago

Parisotto Shannon M

CEVP, Disc, Safety Assessment

EVP
Sell2.0K$294.12$600K

Aug 11, 2026

3 months ago

Girshick Birgit

CEO

CEO
Sell6.5K$279.90$1.82M

Aug 11, 2026

3 months ago

Parisotto Shannon M

CEVP, Disc, Safety Assessment

EVP
Sell3.7K$279.66$1.04M

Aug 10, 2026

3 months ago

Foster James C

Dir

Director
Sell28.7K$275.00$7.90M

Aug 6, 2026

3 months ago

Knell Michael Gunnar

SVP, Finance, CAO

SVP
Sell6.6K$260.38$1.73M

Aug 6, 2026

3 months ago

Creamer Victoria L

EVP, Chief People Officer

EVP
Sell4.2K$259.16$1.08M

Aug 5, 2026

3 months ago

Parisotto Shannon M

CEVP, Disc, Safety Assessment

EVP
Sell5.0K$263.00$1.33M

Jun 29, 2026

4 months ago

Foster James C

Dir

Director
Sell75.0K$225.00$16.88M

Mar 3, 2026

8 months ago

Laplume Joseph W

EVP, Corp Strategy, Develop

EVP
Buy25$174.54$4K

Aug 22, 2025

15 months ago

Laplume Joseph W

EVP, Corp Strategy, Develop

EVP
Sell400$163.72$65K

Aug 18, 2025

15 months ago

Laplume Joseph W

EVP, Corp Strategy, Develop

EVP
Sell800$157.60$126K

Aug 7, 2025

15 months ago

Laplume Joseph W

EVP, Corp Strategy, Develop

EVP
Sell400$150.04$60K

May 15, 2025

18 months ago

Massaro George

Dir

Director
Sell140$137.58$19K

May 14, 2025

18 months ago

Massaro George

Dir

Director
Sell140$140.74$20K

May 13, 2025

18 months ago

Laplume Joseph W

EVP, Corp Strategy, Develop

EVP
Sell500$145.41$73K

Feb 20, 2025

21 months ago

Foster James C

COB, Pres, CEO

CEO
Buy6.1K$165.01$1.00M

Feb 20, 2025

21 months ago

Girshick Birgit

Corporate EVP, COO

COO
Buy1.5K$164.63$249K

Feb 20, 2025

21 months ago

Laplume Joseph W

EVP, Corp Strategy, Develop

EVP
Sell4.4K$162.50$715K

Nov 7, 2024

24 months ago

Wallman Richard F

Dir

Director
Sell7.6K$216.17$1.65M
Sector & Industry Benchmarks
Unknown Comparison Overview
Industry Buy Conviction6%
CRL Buy Conviction2%
Industry Rank#0 of 570
Volume Contribution0.3%
Total Industry Activity$16.44B

CRL has an insider buy conviction of 2%, compared to the Unknown sector buy average of 6%.

Insider Trading Summary & Commentary
Automated executive transaction analysis for CRL

Over the last 90 days, corporate insiders at CRL (CRL) engaged in a total of 25 transactions reported via SEC Form 4 filings. Among these, 4 were open-market purchases and 21 were sales. The total volume of insider trading reached $56.05M.

The net insider activity for CRL shows a net selling bias of $53.53M. This activity represents a 2% buy ratio, suggesting that insiders are currently bearish on the company's near-term outlook relative to recent history.

The most notable individual transaction was a Sale by Foster James C (Dir), who traded 75.0K shares valued at $16.88M on Jun 29, 2026.

Live Market News & Developments
Aggregated real-time headlines for CRL (CRL)
6 updates

Charles River Laboratories (CRL) Stock Looks Fairly Valued Despite Its 106% Run

Yahoo Finance2d ago

(CRL) Movement as an Input in Quant Signal Sets

Stock Traders DailyYesterday

Charles River (CRL) Stock Could Be 27% Overvalued As Preclinical FDA Collaboration Starts

Yahoo Finance20d ago

Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application

Stock Titan4d ago

Charles River Laboratories International (NYSE:CRL) Stock Forecast & Analyst Predictions

Simply Wall St8d ago

Why Charles River Laboratories (CRL) Stock Is Up Today

Quiver Quantitative30d ago

FAQs About CRL Insider Trading

Answers to common questions regarding corporate filings and executive sentiment for CRL.

Based on SEC Form 4 disclosures, the Insider Confidence Score for CRL is currently 80/100, which reflects a strong accumulation bias. This calculation accounts for a total of 4 purchases and 21 sales by company executives over the last 90 days.

The CEO Conviction Index for CRL is rated as "High Conviction Accumulation". Executive buying is typically a strong vote of confidence as C-level leaders have the most intimate knowledge of their firm's prospects. Officer selling, on the other hand, is often routine and does not automatically signal operational weakness.

No. Insider tracking is a highly informative technical signal that indicates executive sentiment, but it should not be the sole basis for a transaction. Investors should combine this filing analysis with company financials, sector trends, and risk management criteria.